Edgar Filing: O'Neill Julie - Form 4

O'Neill Julie Form 4											
August 30, 2	2017										
FORM	ПЛ									PPROVAL	
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287			
Check th if no long subject to Section 1 Form 4 o Form 5 obligatio may cont See Instri	F CHANGES IN BENEFICIAL OWNERSHIP SECURITIES Section 16(a) of the Securities Exchange Act of 19 Public Utility Holding Company Act of 1935 or S of the Investment Company Act of 1940						Expires: Estimated a burden hou response n	rs per			
1(b).											
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> O'Neill Julie			2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O ALEXI PHARMAC COLLEGE	CEUTICALS, I	(Middle) NC, 100	3. Date of (Month/D 08/28/20	-	ansaction			Director X Officer (give below) EVP. C			
				ndment, Da th/Day/Year)	-			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEW HAV	EN, CT 06510							Form filed by N Person	Aore than One Re	eporting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ar) Executi any		Date, if Transaction(A) or Disposed of Code (Instr. 3, 4 and 5) y/Year) (Instr. 8) (A) or		of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock, par value \$.0001 per share	08/28/2017			Code V S	Amount 11,160 (1)	(D) D	Price \$ 140	26,704	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: O'Neill Julie - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion (Month/Day/Year) Exec or Exercise any Price of (Mo Derivative		Code of		Expiration D (Month/Day/ ve es d d	6. Date Exercisable and Expiration Date (Month/Day/Year)		le and unt of rlying ities : 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Reporting Owners											
I	Reporting Ow	vner Name / Address	Director	r 10% Ov		lationships fficer		Oť	her		
		ARMACEUTICAL EET	LS, INC		E	VP. Global (Operations	3			

Signatures

NEW HAVEN, CT 06510

/s/ Michael Greco, Attorney-in-Fact for Julie D'Neill	08/30/2017		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.